Salvia Polyphenolates Combined with Doxophylline in the Treatment of Patients with Chronic Pulmonary Heart Disease in the Compensated Stage

Abstract

Objective: To statistically determine the effect of salvia polyphenolates combined with doxophylline treatment in patients with chronic pulmonary heart disease in the compensated stage. Methods: From January 2023 to January 2024, 76 patients with chronic pulmonary heart disease in the compensated stage were selected as research subjects. The patients were divided into a research group and a reference group using a randomized numerical table method. The research group was treated with salvia polyphenolates combined with doxophylline, while the reference group received conventional therapy. The treatment effects of the two groups were compared. Results: The patients in the research group, treated with salvia polyphenolates combined with doxophylline, showed maximal ventilation of 73.26 ± 4.83 L/min, left ventricular ejection fraction of 56.14 ± 1.98%, and total effective treatment rate of 94.74%. These results were better than those of the reference group. The differences between the data of the research group and the reference group were statistically significant (P < 0.05). Conclusion: For patients with chronic pulmonary heart disease in the compensated stage, treatment with salvia polyphenolates combined with doxophylline significantly improves maximum ventilation and left ventricular ejection fraction, and also results in a higher total effective treatment rate.